Regulus Therapeutics Inc  

(Public, NASDAQ:RGLS)   Watch this stock  
Find more results for RGLS
3.46
+0.03 (0.87%)
Jul 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.41 - 3.54
52 week 2.44 - 10.60
Open 3.44
Vol / Avg. 441,341.00/1.05M
Mkt cap 183.16M
P/E     -
Div/yield     -
EPS -1.20
Shares 52.78M
Beta 1.82
Inst. own 68%
Aug 2, 2016
Q2 2016 Regulus Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 13, 2016
Regulus Therapeutics Inc at Cantor Fitzgerald Healthcare Conference
Jun 27, 2016
Regulus Therapeutics Inc Reports Clinical Hold of RG-101 - Webcast
Jun 10, 2016
Regulus Therapeutics Inc at Jefferies Healthcare Conference
Jun 9, 2016
Regulus Therapeutics Inc Annual Shareholders Meeting (Estimated)
Jun 7, 2016
Regulus Therapeutics Inc to Discuss Top-line Results from Phase II studies of RG-101 Corporate Call
Jun 2, 2016
Regulus Therapeutics Inc Annual Shareholders Meeting
May 25, 2016
Regulus Therapeutics Inc at UBS Global Healthcare Conference
May 12, 2016
Regulus Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 2, 2016
Q1 2016 Regulus Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -4336.81% -268.55%
Operating margin -4371.78% -272.50%
EBITD margin - -256.07%
Return on average assets -63.19% -35.67%
Return on average equity -73.55% -43.54%
Employees 94 -
CDP Score - -

Address

3545 John Hopkins Ct Ste 210
SAN DIEGO, CA 92121-1110
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Officers and directors

Stelios B. Papadopoulos Ph.D. Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Paul C. Grint M.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Joseph P. Hagan Principal Financial Officer, Chief Operating Officer, Principal Accounting Officer
Age: 46
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Director
Age: 61
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 57
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters
Mark G. Foletta CPA Independent Director
Age: 54
Bio & Compensation  - Reuters
William H. Rastetter Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters